COVID-19 may worsen radiation side effects in breast cancer patients
NCT ID NCT07188116
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study examines whether having COVID-19 increases the chance of lung inflammation (radiation pneumonitis) in breast cancer patients receiving radiation therapy. Researchers will review medical records of 200 patients to compare outcomes between those who had COVID-19 and those who did not. The goal is to understand if COVID-19 adds extra risk, which could help guide future treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If this study finds a link, it could help doctors better manage radiation therapy for breast cancer patients who have had COVID-19.
What could go wrong
This is a small, single-center retrospective study, so results may not apply to everyone. It only looks at past records, so it cannot prove cause and effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Hospital, Department of Oncology, Hangzhou, China, 310030
Hangzhou, Zhejiang, 310030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••